ABIVAX Société Anonyme (AAVXF)
OTCMKTS · Delayed Price · Currency is USD
7.28
0.00 (0.00%)
Jul 15, 2025, 4:00 PM EDT
ABIVAX Société Anonyme Revenue
ABIVAX Société Anonyme had revenue of 4.01M EUR in the half year ending December 31, 2024, with 78.20% growth. This brings the company's revenue in the last twelve months to 10.59M, up 128.98% year-over-year. In the year 2024, ABIVAX Société Anonyme had annual revenue of 10.79M with 135.94% growth.
Revenue (ttm)
10.59M EUR
Revenue Growth
+128.98%
P/S Ratio
51.01
Revenue / Employee
153.45K EUR
Employees
69
Market Cap
583.72M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 10.79M | 6.22M | 135.94% |
Dec 31, 2023 | 4.57M | 69.00K | 1.53% |
Dec 31, 2022 | 4.51M | 302.00K | 7.19% |
Dec 31, 2021 | 4.20M | 4.19M | 29,921.43% |
Dec 31, 2020 | 14.00K | 21.00K | -300.00% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
ABIVAX Société Anonyme News
- 4 weeks ago - Abivax Announces Results of its June 6, 2025 Annual General Meeting - GlobeNewsWire
- 6 weeks ago - Abivax reports Q1 results - Seeking Alpha
- 6 weeks ago - Abivax Presents First Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis - GlobeNewsWire
- 3 months ago - Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones - GlobeNewsWire
- 3 months ago - Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors - GlobeNewsWire
- 3 months ago - ABIVAX: Undercovered, Late-Stage French Company With Upcoming Catalysts - Seeking Alpha
- 3 months ago - Abivax publishes financial reports with the French and U.S. securities regulatory agencies - GlobeNewsWire